Identification of Biomarker Signatures and Candidate Drugs in Non-Small Cell Lung Cancer
Paper Details
Identification of Biomarker Signatures and Candidate Drugs in Non-Small Cell Lung Cancer
Abstract
Lung cancer is the most important health risk for human in worldwide. Non-small cell lung cancer (NSCLC) is the most common cause of premature death from malignant disease. The aim of the study was to determine the pathways and expression profile of the genes to discover molecular signature at RNA and protein levels which could serve as potential drug targets for therapeutics innovation and the identification of novel targets. Eight proteins, six TFs and seven miRNAs came into prominence as potential drug targets. The differential expression profiles of these reporter biomolecules were cross-validated by independent RNA-Seq and miRNA-Seq. Risk discrimination performance of the reporter biomolecules NPR3, JUN, PPARG, TP53, CKMT1A, SP3 and TFAP2A were also evaluated. Total 213 drugs and 7 proteins was found for non-small cell lung cancer through dgidb. Among these identified drugs seven drugs such as- Gemcitabine, Carboplatin, paclitaxel, Docetaxel, Crizotinib, Bevacizumab and Gemcitabine is used for NSCLC which is approved by National Cancer Institute. The molecular signatures and repurposed drugs presented here permit further attention for experimental studies which are offer significant potential as biomarkers and candidate therapeutics for precision medicine approaches to clinical management of NSCLC.
Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD. 2013. Epidemiology of lung cancer: Diagnosis and management of lung cancer. Third Edition: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143, e1S, e29S.
Anaya J. 2016. OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. PeerJ Computer Science 2, e67.
Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall 1 KA, Phillippy KH, Sherman PM, Holko M, Yefanov A, Lee H, Zhang N, Robertson CL, Serova N, Davis S, Alexandra Soboleva A. 2013. NCBI GEO: Archive for functional genomics data sets – Update. Nucleic Acids Research 41, 991-995.
Bovolenta LA, Acencio ML, Lemke N. 2012. HTRIdb: An open-access database for experimentally verified human transcriptional regulation interactions. BMC Genomics 13, 405.
Calimlioglu B, Karagoz K, Sevimoglu T, Kilic E, Gov E, Arga KY. 2015. Tissue-Specific Molecular Biomarker Signatures of Type 2 Diabetes: An Integrative Analysis of Transcriptomics and Protein-Protein Interaction Data. OMICS 19, 563-573.
Chin C, Chen S, Wu H. 2009. Cyto-Hubba: A Cytoscape Plug-in for Hub Object Analysis in Network Biology. Genome Informatics 5, 2-3.
Chou CH, Chang NW, Shrestha S, Hsu SD, Lim YL, Lee WH, Yang CD, Hong HC, Wei TY, Tu SJ, Tsai TR, Ho SY, Jian TY, Wu HY, Chen PR, Lin NC, Huang HT, Yang TL, Pai CY, Tai CS, Chen WL, Huang CY, Liu CC, Weng SL, Liao KW, Hsu WL, Huang HD. 2016. miRTarBase 2016: Updates to the experimentally validated miRNA-target interactions database. Nucleic Acids Research 44, D239-D247.
Cotto KC, Wagner AH, Feng Y, Kiwala S, Coffman AC, Spies G, Wollam A, Spies NC, Griffith OL, Griffith M. 2017. DGIdb 3.0: a redesign and expansion of the drug–gene interaction database. Nucleic Acids Research 17.
D’Amico TA. 2008. Molecular biologic staging of lung cancer. The Annals of Thoracic Surgery 85, S737- S742.
Dzobo K, Senthebane DA, Rowe A, Thomford NE, Mwapagha LM, Al-Awwad N, Dandara C, Parker MI. 2016. Cancer Stem Cell Hypothesis for Therapeutic Innovation in Clinical Oncology? Taking the Root Out, Not Chopping the Leaf. OMICS 20(12), 681-691.
Gentleman RC, Carey VJ and Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacas S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith G, Tierney L, Yang JY, Zhang J. 2004. Bioconductor: open software development for computational biology and bioinformatics. Genome Biology 5, R80.
Gollapalli K, Ghantasala S, Atak A, Rapole S, Moiyadi A, Epari S, Srivastava S. 2017. Tissue Proteome Analysis of Different Grades of Human Gliomas Provides Major Cues for Glioma Pathogenesis. OMICS 21(5), 275-284.
Golub TR. 2001. Genome-wide views of cancer. The New England Journal of Medicine 344, 601–602.
Gov E, Kori M, Arga KY. 2017. Multiomics Analysis of Tumor Microenvironment Reveals Gata2 and miRNA-124-3p as Potential Novel Biomarkers in Ovarian Cancer. OMICS 21, 603-615.
Hu M, Qian C, Hu Z, Fei B, Zhou H. 2017. Biomarkers in Tumor Microenvironment? Upregulation of Fibroblast Activation Protein-α Correlates with Gastric Cancer Progression and Poor Prognosis. OMICS 21(1), 38-44.
Huang Z, Cheng Y, Chiu PM, Cheung FM, Nicholls JM, Kwong DL, Lee AW, Zabarovsky ER, Stanbridge EJ, Lung HL, Lung ML. 2012. Tumor suppressor Alpha B-crystallin (CRYAB) associates with the cadherin/catenin adherens junction and impairs NPC progression-associated properties. Oncogene 31, 3709–3720.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. 2007. Cancer statistics, CA: A Cancer Journal for Clinicians 57, 43-66.
Karagoz K, Sevimoglu T, Arga KY. 2016. Integration of multiple biological features yields high confidence human protein interactome. Journal of Theoretical Biology 403, 85-96.
Kori M, Gov E, Arga KY. 2016. Molecular signatures of ovarian diseases: Insights from network medicine perspective. Systems Biology in Reproductive Medicine 62, 266–282.
Lopez-Ayllon BD, Moncho-Amor V, Abarrategi A, Ibañez-de-Cáceres I, Castro-Carpeño J, Belda-Iniesta C, Perona R, Sastre L. 2014. Cancer stem cells and cisplatin-resistant cells isolated from non-small-lung cancer cell lines constitute related cell populations. Cancer Medicine 3(5), 1099-111.
Miskolczi Z, Smith MP, Rowling EJ, Ferguson J, Barriuso J, Wellbrock C. 2018. Collagen abundance controls phenotypes through lineage-specific microenvironment sensing. Oncogene. http://dx.doi.org/10.1038/s41388018-0209-0.
Patil KR, Nielsen J. 2005. Uncovering transcriptional regulation of metabolism by using metabolic network topology. Proceedings of the National Academy of Sciences USA 102, 2685-2689.
Sevimoglu T, Arga KY. 2014. The role of protein interaction networks in systems biomedicine. Computational and Structural Biotechnology Journal 11, 22-27.
Tian Q, Stepaniants SB, Mao M, Weng L, Feetham MC, Doyle MJ, Yi EC, Dai H, Thorsson V, Eng J, Goodlett D, Berger JP, Gunter B, Linseley PS, Stoughton RB, Aebersold R, Collins SJ, Hanlon WA, Hood LE. 2004. Integrated genomic and proteomic analyses of gene expression in Mammalian cells. Molecular & Cellular Proteomics 3(10), 960-969.
Turanli B, Arga KY. 2017. Systems biomedicine acts as a driver for the evolution of pharmacology. Annals of Pharmacology and Pharmaceutics 2, 1087.
Md. Parvez Mosharaf, Amina Rownaq, S.M. Shahinul Islam, Md. Nurul Haque Mollah (2020), Identification of Biomarker Signatures and Candidate Drugs in Non-Small Cell Lung Cancer; IJB, V16, N1, January, P107-119
https://innspub.net/identification-of-biomarker-signatures-and-candidate-drugs-in-non-small-cell-lung-cancer/
Copyright © 2020
By Authors and International
Network for Natural Sciences
(INNSPUB) https://innspub.net
This article is published under the terms of the
Creative Commons Attribution License 4.0